Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors
May 02 2022 - 4:01PM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing
company focused on developing potentially curative therapeutics
leveraging CRISPR-based technologies, today announced the
appointment of Muna Bhanji, R.Ph., to its board of directors.
“We welcome Muna whose deep expertise in global
commercialization and market access will be critical to Intellia as
we expand our leadership position in the field of genome editing
and move closer to commercializing potentially curative treatments
for people with life-threatening diseases,” said Intellia President
and Chief Executive Officer John Leonard, M.D. “We are very
fortunate to benefit from Muna’s extensive experience navigating
U.S. and global healthcare systems to improve patient access to
innovative medicines. We are thrilled with her joining our board
and look forward to her many contributions to our future
success.”
Ms. Bhanji brings more than 30 years of strategic and
operational experience in the biopharmaceutical industry to
Intellia’s board, including a proven track record of driving growth
across a broad portfolio of medicines and vaccines. She built her
career at Merck & Co., where she held several senior leadership
roles within U.S. based sales, marketing, managed markets and
commercial operations, global franchise business units, and global
market access and policy. She is the founder and president of Tiba
Global Access, a commercialization and market access strategy
consultancy serving the biopharmaceutical industry. Ms. Bhanji
serves on the board of directors for several companies, including
Cytokinetics (NASDAQ: CYTK), Ardelyx, Inc. (NASDAQ: ARDX) and
Veracyte, Inc. (NASDAQ: VCYT). She also is a member of the board of
Corus International, an international humanitarian organization
working at the intersection of poverty alleviation and healthcare.
Ms. Bhanji earned her B.S. in Pharmacy from Rutgers School of
Pharmacy and an MBA from St. Joseph’s University.
About Intellia TherapeuticsIntellia
Therapeutics, a leading clinical-stage genome editing company, is
developing novel, potentially curative therapeutics leveraging
CRISPR-based technologies. To fully realize the transformative
potential of CRISPR-based technologies, Intellia is pursuing two
primary approaches. The company’s in vivo programs use
intravenously administered CRISPR as the therapy, in which
proprietary delivery technology enables highly precise editing of
disease-causing genes directly within specific target tissues.
Intellia’s ex vivo programs use CRISPR to create the therapy by
using engineered human cells to treat cancer and autoimmune
diseases. Intellia’s deep scientific, technical and clinical
development experience, along with its robust intellectual property
portfolio, have enabled the company to take a leadership role in
harnessing the full potential of genome editing to create new
classes of genetic medicine. Learn more at intelliatx.com. Follow
us on Twitter @intelliatx.
Intellia Forward-Looking StatementsThis press
release contains “forward-looking statements” of Intellia
Therapeutics, Inc. (“Intellia”, “we” or “our”) within the meaning
of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to, express
or implied statements regarding Intellia’s beliefs and expectations
regarding the safety, efficacy and advancement of our clinical
programs and the anticipated contribution of the members of our
board of directors, specifically Ms. Muna Bhanji, and our
executives to our operations and progress.
Any forward-looking statements in this press release are based
on management’s current expectations and beliefs of future events,
and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those
set forth in or implied by such forward-looking statements. These
risks and uncertainties include, but are not limited to: risks
related to our ability to protect and maintain our intellectual
property position; risks related to our relationship with third
parties, including our licensors and licensees; risks related to
the ability of our licensors to protect and maintain their
intellectual property position; uncertainties related to regulatory
agencies’ evaluation of regulatory filings and other information
related to our product candidates; uncertainties related to the
authorization, initiation and conduct of studies and other
development requirements for our product candidates; the risk that
any one or more of our product candidates, including those that are
co-developed, will not be successfully developed and
commercialized; the risk that the results of preclinical studies or
clinical studies will not be predictive of future results in
connection with future studies; and the risk that our
collaborations with Regeneron or our other collaborations will not
continue or will not be successful. For a discussion of these and
other risks and uncertainties, and other important factors, any of
which could cause Intellia’s actual results to differ from those
contained in the forward-looking statements, see the section
entitled “Risk Factors” in Intellia’s most recent annual report on
Form 10-K and quarterly report on Form 10-Q, as well as discussions
of potential risks, uncertainties, and other important factors in
Intellia’s other filings with the Securities and Exchange
Commission (“SEC”). All information in this press release is as of
the date of the release, and Intellia undertakes no duty to update
this information unless required by law.
Intellia Contacts
Investors:Ian KarpSenior Vice President,
Investor Relations and Corporate
Communications+1-857-449-4175ian.karp@intelliatx.com
Lina LiDirector, Investor Relations and Corporate
Communications+1-857-706-1612lina.li@intelliatx.com
Media:Matt Crenson Ten Bridge
Communications+1-917-640-7930media@intelliatx.commcrenson@tenbridgecommunications.com
Ardelyx (NASDAQ:ARDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ardelyx (NASDAQ:ARDX)
Historical Stock Chart
From Sep 2023 to Sep 2024